A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer

Autor: Iain R. Macpherson, Pavlina Spiliopoulou, Saeed Rafii, Matilde Saggese, Richard D. Baird, Javier Garcia-Corbacho, Antoine Italiano, Jacques Bonneterre, Mario Campone, Nicola Cresti, John Posner, Yousuke Takeda, Akinori Arimura, James Spicer

Publikováno v: Breast Cancer Research, Vol 22, Iss 1, Pp 1-9 (2019)

Abstract Background Epertinib (S-222611) is a potent reversible inhibitor of HER2, EGFR and HER4. This trial evaluated the safety, tolerability, pharmacokinetics and antitumour activity of daily oral epertinib combined with trastuzumab (arm A), with

Externí odkaz: https://doaj.org/article/1caffbf612894f738efaee3a4d3d13dc

A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer

Autor: Javier Garcia-Corbacho, James Spicer, Jacques Bonneterre, Iain R. Macpherson, Pavlina Spiliopoulou, Mario Campone, Saeed Rafii, Richard D. Baird, J Posner, Matilde Saggese, Antoine Italiano, Yousuke Takeda, A Arimura, Nicola Cresti

Publikováno v: MacPherson, I R, Spiliopoulou, P, Rafii, S, Saggese, M, Baird, R D, Garcia-Corbacho, J, Italiano, A, Bonneterre, J, Campone, M, Cresti, N, Posner, J, Takeda, Y, Arimura, A & Spicer, J 2019, ' A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer ', Breast Cancer Research, vol. 22, 1 . https://doi.org/10.1186/s13058-019-1178-0
Breast Cancer Research : BCR
Breast Cancer Research, Vol 22, Iss 1, Pp 1-9 (2019)

Background Epertinib (S-222611) is a potent reversible inhibitor of HER2, EGFR and HER4. This trial evaluated the safety, tolerability, pharmacokinetics and antitumour activity of daily oral epertinib combined with trastuzumab (arm A), with trastuzum

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68c296f54e78364b1373c4fc5eded6ac
https://www.repository.cam.ac.uk/handle/1810/301079

Convenient indole synthesis from ethynylanilines with a polymer-supported fluoride

Autor: Naoyuki Suzuki, Akito Yasuhara, Takao Sakamoto, Yousuke Takeda, Takashi Yoshino

Publikováno v: Tetrahedron Letters. 43:6579-6582

The cyclization reaction of ethynylanilines having phenyl, alkyl, methoxy, cyano, chloro, and ethoxycarbonyl groups with (polystyrylmethyl)trimethylammonium fluoride in dry MeCN under an argon atmosphere at 100°C proceeded in good yields to give the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9888ea9361cf4a2b54d86885ee2723cd
https://doi.org/10.1016/s0040-4039(02)01439-9

ChemInform Abstract: Synthesis of 2,3-Disubstituted Indole Using Palladium(II)-Catalyzed Cyclization with Alkenylation Reaction

Autor: Akito Yasuhara, Takao Sakamoto, Naoyuki Suzuki, Yousuke Takeda

Publikováno v: ChemInform. 33

The reaction of ethyl 2-ethynylphenylcarbamate derivative with alkenes in the presence of a palladium(II) catalyst, copper dichloride and tetrabutylammonium fluoride (TBAF) produced 2-substituted 3-ethenylindoles during refluxing. The intramolecular

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::febd1cf12e19ebc5e50b4c723bc1f4cc
https://doi.org/10.1002/chin.200230140

Synthesis of 2,3-disubstituted indole using palladium(II)-catalyzed cyclization with alkenylation reaction

Autor: Akito Yasuhara, Naoyuki Suzuki, Yousuke Takeda, Takao Sakamoto

Publikováno v: Chemicalpharmaceutical bulletin. 50(2)

The reaction of ethyl 2-ethynylphenylcarbamate derivative with alkenes in the presence of a palladium(II) catalyst, copper dichloride and tetrabutylammonium fluoride (TBAF) produced 2-substituted 3-ethenylindoles during refluxing. The intramolecular

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acab8203d713a912697adf1e65b9ed2f
https://pubmed.ncbi.nlm.nih.gov/11848216